-
cds.ahrq.gov/sites/default/files/cds/artifact/logic/2023-10/hook.json
January 01, 2023 - ": [{
"conditionExpression": "NoDDimerNoWells",
"card": {
"summary": "Please assess … PE risk and D-dimer before ordering a CTPA.",
"detail": "It is recommended to assess the patient's … ordering a CTPA.",
"detail": "Since the D-dimer level is not elevated, it is recommended to assess
-
cds.ahrq.gov/sites/default/files/cds/artifact/1141/Warfarin%20and%20NSAIDs%20V.8.pdf
September 08, 2020 - And
Yes No
Assess risk and take
action if necessary
Possible increased risk
of bleeding Is patient … Yes
Start patient on proton
pump inhibitor
Assess risk and take
action if necessary
Possible increased
-
cds.ahrq.gov/sites/default/files/cds/artifact/logic/2023-10/CQL%20to%20CDS%20Hooks%20cards_0.txt
January 01, 2023 - Mapping of CQL conditions to CDS Hooks cards
Condition: NoDDimerNoWells
Card: It is recommended to assess … Condition: NotElevatedDDimerNoWells
Card: Since the D-dimer level is not elevated, it is recommended to assess
-
cds.ahrq.gov/sites/default/files/cds/artifact/1146/Warfarin%20and%20SSRIs%20Graph%20V.%205.pdf
March 11, 2019 - Warfarin
Type of
Antidepressant
Assess … risk and
take action if
necessary
Increased GI and
non-GI bleeding
risk is possible
Assess risk
-
cds.ahrq.gov/sites/default/files/cds/artifact/1141/Warfarin-NSAIDs%20MDIA%20Implementation%20Guide.docx
November 11, 2019 - Yellow: Usually Avoid Combination or Minimize Risk
· For Warfarin – NSAIDS rule:
· Recommendation: Assess … MG Oral Tablet
Naproxen sodium 550 MG Oral Tablet
Omeprazole 40 MG Delayed Release Oral Capsule
Assess … Patient is not on PPI or misoprostol
Warfarin Sodium 4 MG Oral Tablet
Sulindac 200 MG Oral Tablet
N/A
Assess … PPI or misoprostol
Warfarin Sodium 10 MG Oral Tablet
Ketorolac Tromethamine 10 MG Oral Tablet
N/A
Assess … PPI or misoprostol
Warfarin Sodium 10 MG Oral Tablet
Ketorolac Tromethamine 10 MG Oral Tablet
N/A
Assess
-
cds.ahrq.gov/cedar/AHRQ_CEDAR_Final_Project_Report_09_29_2022.pdf
January 01, 2022 - To accommodate the need to assess FAIRness, MITRE created a new tool to assess repository
FAIRness, … C-FAIR adapted the FAIR Guiding
Principles to assess the CEPI repositories themselves instead of the … MITRE used C-FAIR to assess the CEPI repositories four times. … MITRE and AAFP tested CEDAR in a real-
world setting to assess the feasibility of its implementation … Environmental Scan Assess other CEPI, AHRQ Digital Health, and AHRQ
evidence resources and programs
-
cds.ahrq.gov/taxonomy/term/147981
August 23, 2024 - Search All AHRQ Sites
Careers
Contact Us
Español
FAQs
Email Updates
-
cds.ahrq.gov/cdsconnect/artifact-type/risk-assessment
May 31, 2022 - Search All AHRQ Sites
Careers
Contact Us
Español
FAQs
Email Updates
-
cds.ahrq.gov/cdsconnect/keywords/risk-assessment
November 30, 2020 - Search All AHRQ Sites
Careers
Contact Us
Español
FAQs
Email Updates
-
cds.ahrq.gov/cdsconnect/keywords/pain-assessment
November 30, 2020 - Search All AHRQ Sites
Careers
Contact Us
Español
FAQs
Email Updates
-
cds.ahrq.gov/taxonomy/term/2136
May 31, 2022 - Search All AHRQ Sites
Careers
Contact Us
Español
FAQs
Email Updates
-
cds.ahrq.gov/sites/default/files/cds/artifact/171/NIOSH_Occupational%20Factors%20Impacting%20Diabetes_Decision%20Log_condensed.pdf
February 01, 2018 - at risk of harm (safety sensitive occupations)
“current job(s)” The intent of the guideline is to assess … ability to
take breaks”, “ability to
eat/drink/take
medication”
These statements are intended to assess
-
cds.ahrq.gov/sites/default/files/workgroups/221/feb-2017-cholesterol-wg-notes.docx
January 01, 2017 - period of 6 years for the LDL-c laboratory result, citing the 2013 ACC/AHA guideline recommendation to assess … lookback period of 6 years for the BP measurements, citing the 2013 ACC/AHA guideline recommendation to assess
-
cds.ahrq.gov/sites/default/files/Lessons%20Learned%20Summary%20Sheet%20CDS%20Connect%20Patient%20Partnering%20Panel%202021.pdf
April 15, 2022 - Self-assess where you and yours live on the continuums of partnership and co-production.
-
cds.ahrq.gov/sites/default/files/cds/artifact/1146/Warfarin-Antidepressants%20MDIA%20Implementation%20Guide.docx
August 29, 2020 - Usually Avoid Combination or Minimize Risk
· For Warfarin – Antidepressants rule:
· Recommendation: Assess … Mirtazapine
Warfarin Sodium 10 MG Oral Tablet
Mirtazapine 45 MG Disintegrating Oral Tablet
N/A
Assess … major bleeding risk factors
Warfarin Sodium 10 MG Oral Tablet
Escitalopram 20 MG Oral Tablet
None
Assess … major bleeding risk factors
Warfarin Sodium 10 MG Oral Tablet
Escitalopram 20 MG Oral Tablet
None
Assess
-
cds.ahrq.gov/sites/default/files/cds/artifact/106/Poster_AAPNCE_10.26.15.pptx
October 13, 2015 - We developed a 62-item questionnaire to assess clinicians’ perspectives on their roles in the evaluation
-
cds.ahrq.gov/cedar/AHRQ_CEDAR_Terms_and_Conditions.pdf
September 28, 2022 - Logs may be accessed and analyzed by Operators to assess the performance of CEDAR and
plan future work
-
cds.ahrq.gov/cdsconnect/artifact/recommendation-7-opioid-therapy-risk-assessment
September 27, 2018 - Search All AHRQ Sites
Careers
Contact Us
Español
FAQs
Email Updates
-
cds.ahrq.gov/sites/default/files/workgroups/216/jan-2017-cholesterol-wg-notes.docx
January 01, 2017 - Cholesterol Management Work Group
Meeting Summary
Date
01/11/2017
Time
3:00 – 5:00 PM ET
AGENDA
· Welcome and introductions
· Discuss ACC/AHA 10-Year ASCVD Risk Assessment Tool Metadata and CDS creation
· Discuss Longitudinal Risk Assessment Tool Metadata, CDS Creation and Shared Decision Making
· Questions to…
-
cds.ahrq.gov/cedar/AHRQ_CEDAR_Environmental_Scan_2020_508.pdf
January 01, 2020 - To assess the feasibility of this type of integration, the team investigated the web site search form … at
http://web.archive.org/web/20160101002421/http://guideline.gov/.
15
• Methods Used to Assess … o I ‒ The USPSTF concludes that the current evidence is insufficient to assess the
balance of benefits … This lack of definition, however, means that many of the existing tools that were developed to
assess … The GRADE system defines a quantitative framework to assess the quality of
clinical evidence and strength